Method for detecting FGFR3 gene mutation to diagnose bladder cancer and kit

A technology of diagnostic kits and detection reagents, applied in the field of clinical diagnosis of diseases, can solve the problems of time-consuming and labor-intensive, inconsistent diagnosis results, and large variation in detection effect and detection rate of detection indicators.

Active Publication Date: 2017-07-21
迪可定(上海)生物科技有限公司
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there are many bladder cancer tumor markers in the prior art, and the detection effect and detection rate of each detection index vary greatly
On the one hand, i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting FGFR3 gene mutation to diagnose bladder cancer and kit
  • Method for detecting FGFR3 gene mutation to diagnose bladder cancer and kit
  • Method for detecting FGFR3 gene mutation to diagnose bladder cancer and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] Unless otherwise specified, the terms used in the present invention have conventional meanings in the field. For the explanation of the terms, for example, refer to "Molecular Cloning (Third Edition)" edited by Sam Brook et al. The technical content of the present invention is described in detail as follows:

[0020] In the first aspect, the present invention provides a method for detecting the 248-249 site mutation in exon 7 of FGFR3 gene, the 366-379 site mutation in exon 10, and the 650-653 site mutation in exon 15 A kit, the kit contains fluorescent labeling probes that specifically recognize FGFR3 gene exon mutations.

[0021] In the present invention, when the mutation of the FGFR3 gene is detected, the mutation-specific probe specifically binds to the genomic DNA, while the wild-type DNA forms a "bubble" due to a single-point mismatch, thereby showing a lower melting point.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a technology for diagnosing a bladder cancer through a molecular biology detection means and particularly provides a method for detecting FGFR3 gene mutation to diagnose the bladder cancer and a kit. The technology comprises the step that exons 7, 10 and 15 of an FGFR3 gene are detected to determine whether mutations exist in the exons or not. A double-blind screen test shows that the positive bladder cancer detection rate of the kit is 91.18%, the false positive rate is 3.23%, and the technology has a good clinical application value.

Description

technical field [0001] The invention belongs to the field of clinical diagnosis of diseases, and in particular relates to a technology for diagnosing bladder cancer by means of molecular biological detection, in particular to a method and kit for diagnosing bladder cancer by detecting FGFR3 gene mutation. Background technique [0002] Urothelial carcinoma of the bladder is the most common malignancy of the urinary tract. The incidence rate of cancer in the 32 tumor registries across the country is 6.69 / 100,000, accounting for 2.52% of all new cases of malignant tumors. According to gender statistics, the incidence rates of bladder cancer in males and females are 10.10 / 100,000 and 3.20 / 100,000, respectively, and males are 3.16 times higher than females. The mortality rate of bladder cancer was 2.53 / 100,000 in 32 tumor registries nationwide, accounting for 1.47% of all malignant tumor deaths. [0003] FGFR3 can lead to activation of tyrosine kinase receptor genes, triggering...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68
CPCC12Q1/6858C12Q1/6886C12Q2600/156C12Q2531/113C12Q2563/107
Inventor 王红卫陈海戈王强张瑞赟
Owner 迪可定(上海)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products